🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
1,179

Quick answer

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. TAK-128

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule terminated

    2 trials

  2. TAK-186

    Takeda

    Squamous Cell Cancer of Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  3. TAK-188

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  4. TAK-226

    Takeda

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  5. TAK-272

    Takeda

    Type 2 Diabetes Mellitus and Microalbuminuria

    phase 2 small molecule completed

    1 trial

  6. TAK-279

    Takeda

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  7. TAK-279

    Takeda

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  8. TAK-279 Placebo (same excipient as TAK-279), ZASOCITINIB

    Takeda

    Moderate to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  9. TAK-279 placebo (same excipient as TAK-279), ZASOCITINIB, ZASOCITINIB

    Takeda

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  10. TAK-280

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  11. TAK-280, SILTUXIMAB, TOCILIZUMAB, TOCILIZUMAB, SILTUXIMAB, TOCILIZUMAB

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule active

    1 trial

  12. TAK-341

    Takeda

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial

  13. TAK-360

    Takeda

    Narcolepsy Type 2

    phase 2 small molecule active

    1 trial

  14. TAK-360

    Takeda

    Idiopathic Hypersomnia

    phase 2 small molecule active

    1 trial

  15. TAK-379

    Takeda

    Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  16. TAK-385

    Takeda

    Uterine Fibroids

    phase 2 small molecule completed

    1 trial

  17. TAK-385

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  18. TAK-411

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 2 mab active

    1 trial

  19. TAK-442

    Takeda

    Venous Thromboembolism

    phase 2 small molecule completed

    1 trial

  20. TAK-442

    Takeda

    Acute Coronary Syndrome

    phase 2 small molecule completed

    1 trial

  21. TAK-448

    Takeda

    Hypogonadotropic Hypogonadism

    phase 2 small molecule terminated

    1 trial

  22. TAK-448

    Takeda

    Low Testosterone

    phase 2 small molecule terminated

    1 trial

  23. TAK-500

    Takeda

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  24. TAK-505

    Takeda

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  25. TAK-583

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule completed

    1 trial

  26. TAK-653

    Takeda

    Treatment-Resistant Depression

    phase 2 small molecule terminated

    1 trial

  27. TAK-659

    Takeda

    AML

    phase 2 small molecule terminated

    1 trial

  28. TAK-662

    Takeda

    Congenital Protein C Deficiency

    phase 2 small molecule completed

    1 trial

  29. TAK-700

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  30. TAK-715 and methotrexate

    Takeda

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  31. TAK-755

    Takeda

    Acute Ischemic Stroke

    phase 2 mab active

    1 trial

  32. TAK-783 and methotrexate

    Takeda

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  33. TAK-788

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  34. TAK-788

    Takeda

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  35. TAK-850

    Takeda

    Influenza

    phase 2 small molecule completed

    1 trial

  36. TAK-850

    Takeda

    Influenza Prevention

    phase 2 small molecule terminated

    1 trial

  37. TAK-850

    Takeda

    Influenza Infection

    phase 2 mab completed

    1 trial

  38. TAK-850 0.5 mL injection

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  39. TAK-853

    Takeda

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  40. TAK-906 Maleate

    Takeda

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  41. TAK-906 Maleate

    Takeda

    Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis

    phase 2 small molecule completed

    1 trial

  42. TAK-919

    Takeda

    Coronavirus Disease (COVID-19)

    phase 2 mab completed

    1 trial

  43. TAK-931

    Takeda

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  44. TAK-935

    Takeda

    Developmental and/or Epileptic Encephalopathies

    phase 2 small molecule completed

    1 trial

  45. TAK-935

    Takeda

    Epilepsy

    phase 2 small molecule completed

    2 trials

  46. TAK-951

    Takeda

    Postoperative Nausea and Vomiting (PONV)

    phase 2 small molecule completed

    1 trial

  47. TAK-954

    Takeda

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  48. TAK-954

    Takeda

    Critical Illness

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.